You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IL15 superagonist

Showing 1 - 25 of 7,384
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV Infection Trial in United States (N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074)

Recruiting
  • HIV Infection
  • N-803 (IL-15 Superagonist)
  • +2 more
  • Los Angeles, California
  • +11 more
Sep 22, 2022

NonHodgkin's Lymphoma Refractory Trial in El Segundo (N803, CD19t-haNK suspension, Cyclophosphamide)

Not yet recruiting
  • NonHodgkin's Lymphoma Refractory
  • El Segundo, California
    CSSIFM
Nov 9, 2022

Human Immunodeficiency Virus Trial in New York, Philadelphia (3BNC117-LS, 10-1074-LS, N803)

Not yet recruiting
  • Human Immunodeficiency Virus
  • New York, New York
  • +2 more
Jul 12, 2022

Lynch Syndrome Trial in Puerto Rico, United States (procedure, drug, other, biological)

Not yet recruiting
  • Lynch Syndrome
  • Biopsy
  • +5 more
  • Phoenix, Arizona
  • +13 more
Sep 16, 2022

Merkel Cell Carcinoma Trial in United States (Avelumab, N-803, haNK™)

Terminated
  • Merkel Cell Carcinoma
  • Avelumab
  • +2 more
  • San Francisco, California
  • +4 more
Jan 7, 2022

COVID-19 Trial in Chongqing (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

Recruiting
  • COVID-19
  • NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
  • Chongqing, China
    Chongqing Public Health Medical Center
Nov 16, 2020

Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Boston (Interleukin-15

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Interleukin-15 Superagonist (N-803)
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 2, 2022

Multiple Myeloma Trial in Little Rock (drug, procedure, biological)

Withdrawn
  • Multiple Myeloma
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
Jul 8, 2020

Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)

Not yet recruiting
  • Hematological Malignancy
  • Fludarabine Phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Esophageal Cancer, Pancreas Cancer, Ovarian Cancer Trial in Edegem (IL15-transpresenting WT1-targeted Dendritic Cell Vaccine)

Not yet recruiting
  • Esophageal Cancer
  • +3 more
  • IL15-transpresenting WT1-targeted Dendritic Cell Vaccine
  • Edegem, Belgium
    Antwerp University Hospital
Jul 19, 2023

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma Trial in Houston (CAR.70/IL15-transduced CB-derived

Not yet recruiting
  • Advanced Renal Cell Carcinoma
  • +2 more
  • CAR.70/IL15-transduced CB-derived NK cells
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Pancreatic Cancer, Ovarian Cancer, Adenocarcinoma Trial in Houston (TROP2-CAR-NK, Cyclophosphamide, Fludarabine)

Not yet recruiting
  • Pancreatic Cancer
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 27, 2023

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 4, 2023

Tumor, Metastatic Melanoma, Melanoma Trial in Houston (OBX-115, Acetazolamide, Cyclophosphamide)

Not yet recruiting
  • Tumor
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Aug 16, 2022

Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides Trial run by the NCI (Recombinant human Interleukin-15

Completed
Has Results
  • Adult T-Cell Lymphoma/Leukemia
  • +2 more
  • Recombinant human Interleukin-15 (rhIL-15)
  • Mogamulizumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 9, 2022

HIV/AIDS Trial in Bangkok (N-803)

Recruiting
  • HIV/AIDS
  • Bangkok, Thailand
    Thai Red Cross AIDS Research Centre
Oct 4, 2021

B-Cell Lymphoma, MDS (MDS), Acute Myeloid Leukemia (AML) Trial in Houston (Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells,

Not yet recruiting
  • B-Cell Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 12, 2022

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Active Non Segmental Vitiligo Trial in Cairo (Narrow band ultraviolet B)

Completed
  • Active Non Segmental Vitiligo
  • Narrow band ultraviolet B
  • Cairo, Helwan, Egypt
    Nourhan Emad
Aug 8, 2022

Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Neuroblastoma
  • Osteosarcoma
  • iC9.GD2.CAR.IL-15 T-cells
  • +2 more
  • Atlanta, Georgia
  • +1 more
Jan 4, 2023

Locally Advanced/Metastatic Solid Tumors Trial in United States (BJ-001, Pembrolizumab)

Recruiting
  • Locally Advanced/Metastatic Solid Tumors
  • Saint Louis, Missouri
  • +4 more
Jun 5, 2022

Clear-Cell Renal Carcinoma Trial run by the NCI (rhIL-15, Avelumab)

Terminated
Has Results
  • Clear-Cell Renal Carcinoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 27, 2022

Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T Infusion)

Not yet recruiting
  • Lung Cancer
  • +2 more
  • iC9.GD2.CAR.IL-15 T Infusion
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Nov 16, 2022